✦ LIBER ✦

Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment

✍ Scribed by Joep de Bruijne; James C. Sullivan; Tara L. Kieffer; Martyn Botfield; Ben Shames; Janke Schinkel; Richard Molenkamp; Christine Weegink; Henk Reesink

Book ID: 116632228
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 315 KB
Volume: 53
Category: Article
ISSN: 1386-6532
DOI: 10.1016/j.jcv.2011.11.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Genotype, serum level of HCV-RNA and res

Genotype, serum level of HCV-RNA and response to interferon-α treatment in patients with chronic hepatitis C

✍ C. Clarysse; C. Van den Eynde; F. Nevens; C. Portier; N. Aelbrecht; J. Fevery; S 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 466 KB

Correlation of serum HCV RNA and alanine

Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin

✍ MYRON J. TONG; SHINN-JANG HWANG; MICHELLE LEFKOWITZ; SHOU-DONG LEE; RUTH L. CO; 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 457 KB

Prediction of treatment outcome with dai

Prediction of treatment outcome with daily high-dose IFN α-2b plus ribavirin in patients with chronic hepatitis C with genotype 1b and high HCV RNA levels: relationship of baseline viral levels and viral dynamics during and after therapy

✍ Shiro Iino; Eiichi Tomita; Hiromitsu Kumada; Hiroshi Suzuki; Joji Toyota; Kendo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB

Serum HCV RNA levels and HCV genotype do

Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study

✍ E. TSOCHATZIS; S. MANOLAKOPOULOS; G. V. PAPATHEODORIDIS; E. HADZIYANNIS; C. TRIA 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

[586] SAFETY, PHARMACOKINETICS AND ANTIV

[586] SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BILB1941, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

✍ A. Erhardt; H. Wedemeyer; Y. Benhamou; C. Moellekens; X. Forns; S. Pol; J.L. Cal 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 153 KB

1054 SAFETY, PHARMACOKINETICS AND ANTIVI

1054 SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BI 207127, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

✍ Larrey, D.; Benhamou, Y.; Lohse, A.W.; Trepo, C.; Moelleken, C.; Bronowicki, J.- 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB